RWJBarnabas Health and Rutgers Cancer Institute held its inaugural Clinical Practice and Research Summit on November 13, 2021.
RWJBarnabas Health and Rutgers Cancer Institute of New Jersey held its inaugural Clinical Practice and Research Summit on November 13, 2021. During the all day workshop, leaders and physicians from both organizations shared their expertise on advances in cancer research and treatment with a focus on clinical trials.
Topics included multiple myeloma, precision medicine, immunotherapy, surgical oncology, biosimilars, Her2+ and triple negative breast cancer, genitourinary cancers, and radiation oncology. Dr. Peter O’Dwyer, Director, Developmental Therapeutics Program at the Abramson Cancer Center and Professor of Medicine, University of Pennsylvania and Co-Chair of the ECOG-ACRIN Cancer Research Group, delivered the keynote address “Precision Medicine, Real-World Data, Health Equity: The Elements of Cancer Research.”
Dr. Andrew Evens Recaps the 2021 Annual Clinical Practice and Research Summit
Dr. Howard Hochster Discusses the Importance of Clinical Trials in Oncology
Dr. Michele Blackwood Discusses Developments in Personalized Breast Cancer Treatment
Panel Discussion: Advances in Surgical Care for Oncology Patients
Panel Discussion: Managing Immunotherapy-Related Adverse Events
Expert Interviews
Several experts were also featured in OncLive®, a platform that covers groundbreaking cancer news with top oncologists.
Andrew M. Evens, DO, MSc, discusses highlights from the 2021 RWJ Annual Clinical and Practice Research Summit. Watch Here
Christian S. Hinrichs, MD, discusses unmet needs with cellular therapies in metastatic epithelial cancer. Watch Here
Shridar Ganesan, MD, PhD, discusses improvements in precision medicine and the need to enroll patients with different molecular subtypes into specifically designed clinical trials. Watch Here
Howard S. Hochster, MD, FACP, discusses treatment considerations for patients with HER2-positive gastric cancer. Watch Here
Deborah L. Toppmeyer, MD, discusses the utility of clinical trials evaluating de-escalated treatment approaches in HER2-positive breast cancer. Watch Here
Saum Ghodoussipour, MD, discusses ongoing trials in non–muscle invasive bladder cancer. Watch Here
Kathleen C. Toomey, medical oncologist, discusses the importance of clinical trials evaluating de-escalated treatment strategies in HER2-positive breast cancer. Watch Here
Mansi R. Shah, MD, discusses ongoing research examining the CAR T-cell therapy ciltacabtagene autoleucel for the treatment of patients with relapsed or refractory multiple myeloma.
Watch Here
Missed the Oncology Summit This Year?
Missed this year’s event? At your convenience you can view the full program here.To learn about the 2022 Summit please contact Bryan Soltes, System Vice President for Network Development, Oncology Services, RWJBarnabas Health at Bryan.Soltes@rwjbh.org.
Photo credit: Alex Delmonico